PMID- 18021496
OWN - NLM
STAT- MEDLINE
DCOM- 20080227
LR  - 20190911
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 24
IP  - 1
DP  - 2008 Jan
TI  - Switching from other antipsychotics to once-daily extended release quetiapine 
      fumarate in patients with schizophrenia.
PG  - 21-32
AB  - OBJECTIVE: To evaluate the clinical benefit, efficacy and tolerability of 
      switching patients experiencing suboptimal efficacy or tolerability with their 
      current antipsychotic to once-daily extended release quetiapine fumarate 
      (quetiapine XR). RESEARCH DESIGN AND METHODS: 12-week, multicenter, open-label 
      study in adult, in- or outpatients with schizophrenia. Quetiapine XR (mg/day) was 
      initiated during a 4-day cross-titration phase (day 1: 300; day 2: 600; days 
      4-84: 400-800 [flexible-dosing]). The primary endpoint was the percentage of 
      patients achieving clinical benefit (improvement on the Clinical Global 
      Impression-Clinical Benefit [CGI-CB] scale). Secondary endpoints included 
      CGI-Improvement (CGI-I) and Positive and Negative Syndrome Scale (PANSS) total 
      scores. Tolerability was assessed by adverse events (AEs), Simpson-Angus Scale 
      (SAS) and Barnes Akathisia Rating Scale (BARS) scores. Changes in rating scale 
      scores were analyzed using analysis of covariance and are presented as least 
      squares mean (LSM) changes using the baseline level as a covariate. RESULTS: Of 
      477 patients switched to quetiapine XR, 77.6% completed treatment. Following 
      switching, 295 of 470 patients adequate for evaluation (62.8%) achieved a 
      clinical benefit (95% confidence interval [CI] 58.4, 67.1; p < 0.0001). 
      Significant improvements in LSM (95% CI) CGI-I of 2.88 (2.67, 3.08) and the LSM 
      change in PANSS total scores of -12.3 (-14.95, -9.58) were observed (both p < 
      0.001). Common AEs included somnolence (17.8%), sedation (15.1%), dizziness and 
      dry mouth (14.0% each). The incidence of extrapyramidal symptoms (EPS) was 8.0%. 
      Mean improvements from baseline in SAS and BARS scores were -2.1 and -0.4, 
      respectively (both p < 0.001). CONCLUSIONS: Switching to quetiapine XR was 
      associated with clinical benefit and good efficacy and tolerability.
FAU - Ganesan, S
AU  - Ganesan S
AD  - Department of Psychiatry, University of British Columbia, Vancouver, Canada. 
      soma.ganesan@vch.ca
FAU - Agambaram, V
AU  - Agambaram V
FAU - Randeree, F
AU  - Randeree F
FAU - Eggens, I
AU  - Eggens I
FAU - Huizar, K
AU  - Huizar K
FAU - Meulien, D
AU  - Meulien D
CN  - Study 147 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00234377
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dibenzothiazepines)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Algorithms
MH  - Antipsychotic Agents/administration & dosage/adverse effects
MH  - Delayed-Action Preparations/administration & dosage/adverse effects
MH  - Dibenzothiazepines/*administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Drug Tolerance/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polypharmacy
MH  - Quetiapine Fumarate
MH  - Schizophrenia/*drug therapy
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Withholding Treatment
EDAT- 2007/11/21 09:00
MHDA- 2008/02/28 09:00
CRDT- 2007/11/21 09:00
PHST- 2007/11/21 09:00 [pubmed]
PHST- 2008/02/28 09:00 [medline]
PHST- 2007/11/21 09:00 [entrez]
AID - 10.1185/030079908x253384 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2008 Jan;24(1):21-32. doi: 10.1185/030079908x253384.